enGene Therapeutics, Inc. (ENGN)
1.80
+0.03
(+1.69%)
USD |
NASDAQ |
Sep 11, 16:00
1.79
-0.01
(-0.56%)
After-Hours: 06:47
enGene Therapeutics Enterprise Value : -112.50M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -112.50M |
| September 10, 2026 | -114.51M |
| September 09, 2026 | -109.15M |
| September 08, 2026 | -104.46M |
| September 04, 2026 | -111.16M |
| September 03, 2026 | -110.49M |
| September 02, 2026 | -106.47M |
| September 01, 2026 | -108.82M |
| August 31, 2026 | -109.82M |
| August 28, 2026 | -110.83M |
| August 27, 2026 | -105.13M |
| August 26, 2026 | -102.45M |
| August 25, 2026 | -107.81M |
| August 24, 2026 | -111.83M |
| August 21, 2026 | -113.84M |
| August 20, 2026 | -114.51M |
| August 19, 2026 | -109.15M |
| August 18, 2026 | -117.86M |
| August 17, 2026 | -119.20M |
| August 14, 2026 | -119.20M |
| August 13, 2026 | -119.87M |
| August 12, 2026 | -119.20M |
| August 11, 2026 | -111.16M |
| August 10, 2026 | -115.85M |
| August 07, 2026 | -112.50M |
| Date | Value |
|---|---|
| August 06, 2026 | -112.50M |
| August 05, 2026 | -112.50M |
| August 04, 2026 | -113.17M |
| August 03, 2026 | -114.51M |
| July 31, 2026 | -113.17M |
| July 30, 2026 | -107.29M |
| July 29, 2026 | -105.28M |
| July 28, 2026 | -107.29M |
| July 27, 2026 | -107.29M |
| July 24, 2026 | -103.27M |
| July 23, 2026 | -98.58M |
| July 22, 2026 | -101.26M |
| July 21, 2026 | -95.90M |
| July 20, 2026 | -99.92M |
| July 17, 2026 | -103.27M |
| July 16, 2026 | -96.57M |
| July 15, 2026 | -97.91M |
| July 14, 2026 | -98.24M |
| July 13, 2026 | -100.59M |
| July 10, 2026 | -97.91M |
| July 09, 2026 | -96.57M |
| July 08, 2026 | -100.59M |
| July 07, 2026 | -96.57M |
| July 06, 2026 | -97.24M |
| July 02, 2026 | -105.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals, Inc. | 1.761B |
| Medicus Pharma Ltd. | 14.37M |
| Xenon Pharmaceuticals, Inc. | 4.750B |
| Psyence Biomedical Ltd. | -- |
| Geron Corp. | 816.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.50M |
| Total Expenses (Quarterly) | 32.50M |
| EPS Diluted (Quarterly) | -0.4661 |
| Earnings Yield | -115.6% |
| Normalized Earnings Yield | -115.29 |